Kenvue Inc
stock17.83
+0.13 (+0.73%)
Closed 12 Oct, 21:00
Good Money Guide Pro Score
Attractive
Attractive investment profile
Technical Analysis
Short-Term Outlook
Bearish
1 bull · 2 bear · 2 neutral
Medium-Term Outlook
Bearish
1 bull · 3 bear · 0 neutral
Price below 50-day MA
Price below 200-day MA
Price below 12-day EMA
Price below 26-day EMA
Neutral momentum zone
MACD above signal line
%K below %D
Price near middle band
Volatility measure — informational only
Volume Indicators
On Balance Volume (OBV)
Volume Accumulation Distribution (VAD)
Market Statistics
Open
17.66
Day High
17.83
Day Low
17.49
Previous Close
17.70
Day Range
17.49 - 17.83
Volume
20.29M
Day Change
+0.13
Market Cap
36441764000
Exchange
NYSE
Sector
Consumer Staples
Last Updated
2026-10-12
Fundamentals
Rate limit reached. Please try again in a minute.
Analyst Forecast
Rate limit reached. Please try again in a minute.
Fundamental Analysis
Unable to load fundamental data
Learn about Kenvue Inc
What is Kenvue Inc?
Kenvue Inc. is a global consumer health company that owns well-known household brands like Tylenol, Listerine, and Neutrogena. Formerly the consumer health division of Johnson & Johnson, it operates as an independent entity focused on developing and marketing science-backed self-care products for personal wellness.
Is Kenvue Inc a good investment?
Kenvue offers the stability of essential consumer products, which often perform reliably even during economic downturns, and provides a steady dividend for income-focused investors. However, the company faces significant competition in the retail market and potential legal challenges related to its legacy product portfolios. Please remember that this information is for educational purposes only and does not constitute financial advice.
How do you invest in Kenvue Inc?
To invest in Kenvue, you can purchase shares directly through a regulated online stockbroker or a trading app that offers access to the New York Stock Exchange where it trades under the ticker symbol KVUE. Many investors also gain exposure to the company through broad-market index funds or consumer-staple-focused exchange-traded funds (ETFs).
Educational content generated by AI — not financial advice.
Time & Sales
No trades yet.
News & Sentiment

Kimberly-Clark (KMB) Secures Consents for Kenvue Notes Amendments in $7 Billion Exchange Offer
Kimberly-Clark (KMB) announced it has secured the necessary consents for amendments to Kenvue Notes as part of its $7 billion exchange offer. This development is a key step towards Kimberly-Clark's pending acquisition of Kenvue, with the settlement of the exchange offers expected after the acquisition closes, likely not before November 2, 2026. The amendments eliminate most restrictive covenants and certain events of default for the Kenvue Notes.
Kimberly-Clark, Kenvue Win Conditional EU Approval for $40 Billion Tie-Up
Kimberly-Clark's $40 billion bid for Kenvue has received conditional approval from the European Union. This approval came after Kimberly-Clark offered to divest its tampon and feminine hygiene brands in the European Economic Area. The European Commission stated that this addresses concerns about potential hindrance to competition in tampon markets in Czech Republic, Estonia, and Slovakia.

EU approves Kimberly-Clark's acquisition of Kenvue, subject to conditions
The European Commission has approved Kimberly-Clark's acquisition of Kenvue, contingent on Kimberly-Clark divesting its tampon and other feminine hygiene brands within the European Economic Area. This measure addresses EU antitrust concerns, ensuring market competition. The brands to be sold include Kotex, Camelia, and Record.
Kimberly-Clark secures consents, offers up to $7B in exchange for Kenvue notes
Kimberly-Clark announced it has secured the necessary consents to amend the indentures for all outstanding Kenvue notes, based on early tenders. The company is offering to exchange these Kenvue notes for up to $7.0 billion of new Kimberly-Clark notes and cash. These amendments will remove most restrictive covenants and certain default events, with settlement expected promptly after expiration, likely aligning with the acquisition of Kenvue.
Kenvue Implements Third Supplemental Indenture, Easing Covenants for Kimberly-Clark's $7 Billion Note Exchange
Kenvue has signed a Third Supplemental Indenture to modify its 2023 base indenture, facilitating Kimberly-Clark's exchange offers for up to $7.0 billion of Kenvue notes. This amendment removes most restrictive covenants, certain events of default, SEC reporting requirements, and some merger/asset transfer restrictions. The changes become active for each note series upon the settlement of its related exchange offer, anticipated around the Kimberly-Clark acquisition closing.
Kimberly-Clark Announces Successful Consent Solicitations for Kenvue Notes and Amendment to Terms of Exchange Offers
Kimberly-Clark announced the successful completion of its consent solicitations for Kenvue Notes and an amendment to the terms of its exchange offers. This news, distributed via PR Newswire, indicates progress on financial arrangements related to Kenvue notes. The announcement is a headline-only item, suggesting a formal update on corporate financial actions.

Form 4 Kenvue Inc For: 11 October By Investing.com
This article announces the filing of Form 4 for Kenvue Inc. on October 11, 2026. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders whenever they trade their company's stock. The article itself contains minimal textual content beyond the headline.

Form 4 Kenvue Inc For: 11 October By Investing.com
This article from Investing.com reports on a Form 4 filing for Kenvue Inc. on October 11, 2026. Form 4 filings are legally required documents by the U.S. Securities and Exchange Commission (SEC) that must be filed by company insiders, such as officers, directors, or beneficial owners, whenever they trade securities in their own company. The article provides the filing date and company name, indicating an insider transaction occurred.

Form 4 Kenvue Inc For: 11 October By Investing.com
This article from Investing.com reports on the filing of Form 4 for Kenvue Inc. on October 11, 2026. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report changes in their ownership of company stock. The article provides the title and date of the filing, along with a minor stock performance detail for KVUE.

Form 4 Kenvue Inc For: 11 October By Investing.com
This article from Investing.com announces the filing of Form 4 for Kenvue Inc. on October 11, 2026. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders whenever they trade shares in their own company. The article provides the title and date of the filing, along with the stock symbol KVUE.
Community Discussion
No posts yet for KVUE — be the first to start the discussion.
Point & Figure Analysis
OHLC
Signals
as of 08 Oct 2026Targets
Famous Investors Holding KVUE
Ken Griffin
11.31M sh · 0.0% of portfolio
$216.14M
NEW
Jim Simons
9.02M sh · 0.2% of portfolio
$172.46M
NEW
Donald Yacktman
8.05M sh · 1.9% of portfolio
$153.85M
NEW
Ken Griffin
1.07M sh · 0.0% of portfolio
$20.51M
NEW
Ken Griffin
650.5K sh · 0.0% of portfolio
$12.43M
NEW
Ken Griffin
393.7K sh · 0.0% of portfolio
$7.52M
NEW
Ray Dalio
311.2K sh · 0.0% of portfolio
$5.95M
NEW
Source: SEC Form 13F, reporting period 30 Jun 2026. 45-day lag applies.
PRO